John L. Berk, MD
Associate Professor
Boston University School of Medicine
Dept of Medicine
Pulmonary, Allergy, Sleep & Critical Care Medicine

MD, Case Western Reserve University




Expertise in Amyloidosis with specific emphasis in Familial and localized amyloid disease; pulmonary fibrosis.

Member
Boston University
Pulmonary Center


Assistant Director
Boston University
Amyloidosis Center


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research


Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Graduate Medical Sciences



2019 Boston Top Doctors


"ALN-TTR02-011, APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Car
09/12/2019 - 09/12/2024 (PI)
Alnylam Pharmaceuticals, Inc.


Protocol ION-682884-CS2: A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomy
03/20/2020 - 03/20/2023 (Subcontract PI)
Pharmaceutical Research Associates, Inc. IonisPharmaceuticals


ALN-TTRSC02, HELIOS-B: A Phase 3, Randomized, Double blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cara
12/04/2019 - 12/04/2022 (PI)
Alnylam Pharmaceuticals, Inc.


Protocol # ION-682844-CS3: A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
11/15/2019 - 11/15/2022 (Subcontract PI)
Pharmaceutical Research Associates, Inc. IonisPharmaceuticals


"A Phase 3, Randomized, Double-Blind, Placebo-controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy"
10/04/2019 - 10/04/2022 (PI)
Eidos Therapeutics, Inc.


An Open-Label, Investigator Study to Evaluate the Short-term (4 Weeks) Effects of TOLCAPONE on Transthyretin Stability in Subjects with Leptomeningeal TTR Amyloidosis (ATTR) with and without CNS…
09/14/2018 - 08/12/2022 (PI)
Corino Therapeutics


Phase 3 Multicenter, Open-label Study to Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826) 20 MG or 80 MG in subjects diagnosed with transthyrtin cardiomyothy.
04/04/2017 - 04/03/2022 (PI)
Pfizer, Inc.


Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with
03/29/2016 - 03/28/2022 (PI)
Alnylam Pharmaceuticals, Inc.


HELIOS-A: A Phase 3 Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with hATTR Amyloidosis
03/28/2019 - 03/27/2022 (PI)
Alnylam Pharmaceuticals, Inc.


A study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease
03/27/2019 - 03/26/2022 (Co-Investigator)
PI: Andrea Havasi, MD
Alnylam Pharmaceuticals, Inc.


Showing 10 of 29 results. Show All Results


Title


Yr Title Project-Sub Proj Pubs
2009 Effect of diflunisal (IND68092) on familial amyloidosis 5R01NS051306-05 9
2008 Effect of diflunisal (IND68092) on familial amyloidosis 5R01NS051306-04 9
2007 THE EFFECT OF DIFLUNISAL ON HEREDITARY AMYLOIDOSIS 2M01RR000533-39-8163 503
2007 Effect of diflunisal (IND68092) on familial amyloidosis 5R01NS051306-03 9
2007 Effect of diflunisal on familial amyloidosis 5R01FD002532-03 2
2006 Effect of diflunisal (IND68092) on familial amyloidosis 5R01NS051306-02 9
2006 Effect of diflunisal on familial amyloidosis 5R01FD002532-02 2
2005 Effect of diflunisal (IND68092) on familial amyloidosis 1R01NS051306-01 9
2001 ADRENAL INSUFFICIENCY IN PRIMARY SYSTEMIC AMYLOIDOSIS 5M01RR000533-33-353 503
2000 ADRENAL INSUFFICIENCY IN PRIMARY SYSTEMIC AMYLOIDOSIS 5M01RR000533-32-353 503
Showing 10 of 15 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Brannagan TH, Auer-Grumbach M, Berk JL, Briani C, Bril V, Coelho T, Damy T, Dispenzieri A, Drachman BM, Fine N, Gaggin HK, Gertz M, Gillmore JD, Gonzalez E, Hanna M, Hurwitz DR, Khella SL, Maurer MS, Nativi-Nicolau J, Olugemo K, Quintana LF, Rosen AM, Schmidt HH, Shehata J, Waddington-Cruz M, Whelan C, Ruberg FL. ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable. Orphanet J Rare Dis. 2021 05 06; 16(1):204.View Related Profiles. PMID: 33957949; PMCID: PMC8100737; DOI: 10.1186/s13023-021-01834-0;
     
  2. Coelho T, Ando Y, Benson MD, Berk JL, Waddington-Cruz M, Dyck PJ, Gillmore JD, Khella SL, Litchy WJ, Obici L, Monteiro C, Tai LJ, Viney NJ, Buchele G, Brambatti M, Jung SW, St L O'Dea L, Tsimikas S, Schneider E, Geary RS, Monia BP, Gertz M. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. Neurol Ther. 2021 Jun; 10(1):375-389. PMID: 33638113; PMCID: PMC8140170; DOI: 10.1007/s40120-021-00235-6;
     
  3. Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ, Boman K, Gundapaneni B, Patterson TA, Schwartz JH, Sultan MB, Maurer MS. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT. JACC Heart Fail. 2021 02; 9(2):115-123. PMID: 33309574
     
  4. Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol. 2021 01; 20(1):49-59. PMID: 33212063
     
  5. Dyck PJB, Coelho T, Waddington Cruz M, Brannagan TH, Khella S, Karam C, Berk JL, Polydefkis MJ, Kincaid JC, Wiesman JF, Litchy WJ, Mauermann ML, Ackermann EJ, Baker BF, Jung SW, Guthrie S, Pollock M, Dyck PJ. Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis. Muscle Nerve. 2020 10; 62(4):509-515.View Related Profiles. PMID: 32654156; PMCID: PMC7540369; DOI: 10.1002/mus.27023;
     
  6. Coelho T, Adams D, Conceição I, Waddington-Cruz M, Schmidt HH, Buades J, Campistol J, Berk JL, Polydefkis M, Wang JJ, Chen J, Sweetser MT, Gollob J, Suhr OB. A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis. Orphanet J Rare Dis. 2020 07 08; 15(1):179. PMID: 32641071; PMCID: PMC7341568; DOI: 10.1186/s13023-020-01399-4;
     
  7. Moshe-Lilie O, Dimitrova D, Heitner SB, Brannagan TH, Zivkovic S, Hanna M, Masri A, Polydefkis M, Berk JL, Gertz MA, Karam C. TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients. Amyloid. 2020 Dec; 27(4):250-253. PMID: 32578459
     
  8. Brannagan TH, Wang AK, Coelho T, Waddington Cruz M, Polydefkis MJ, Dyck PJ, Plante-Bordeneuve V, Berk JL, Barroso F, Merlini G, Conceição I, Hughes SG, Kwoh J, Jung SW, Guthrie S, Pollock M, Benson MD, Gertz M. Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial. Eur J Neurol. 2020 08; 27(8):1374-1381. PMID: 32343462; PMCID: PMC7496583; DOI: 10.1111/ene.14285;
     
  9. Takumi K, Staziaki PV, Hito R, Nadgir RN, Berk JL, Andreu-Arasa VC, Chavez W, Sakai O. Amyloidosis in the head and neck: CT findings with clinicopathological correlation. Eur J Radiol. 2020 Jul; 128:109034.View Related Profiles. PMID: 32438260; DOI: 10.1016/j.ejrad.2020.109034;
     
  10. Obici L, Berk JL, González-Duarte A, Coelho T, Gillmore J, Schmidt HH, Schilling M, Yamashita T, Labeyrie C, Brannagan TH, Ajroud-Driss S, Gorevic P, Kristen AV, Franklin J, Chen J, Sweetser MT, Wang JJ, Adams D. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid. 2020 Sep; 27(3):153-162. PMID: 32131641
     
Showing 10 of 102 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 102 publications over 26 distinct years, with a maximum of 11 publications in 2018

YearPublications
19871
19911
19931
19942
19962
19983
19993
20002
20012
20023
20032
20043
20054
20071
20101
20117
20125
20135
20144
20157
20164
201710
201811
20197
20209
20212
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

amyloid lung disease
amyloidosis
familial amyloidotic polyneuropathy
pleural effusions
pulmonary fibrosis
tracheobronchial amyloidosis
Contact for Mentoring:

72 E. Concord St Housman (R)
Boston MA 02118
Google Map


Berk's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department